Limits...
Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway.

Su LY, Shi YX, Yan MR, Xi Y, Su XL - Acta Pharmacol. Sin. (2015)

Bottom Line: Treatment of HCT116 cells with ACBPs (35 μg/mL) for 4-6 days significantly inhibited the cell growth.Furthermore, treatment of HCT116 cells with ACBPs (35 μg/mL) for 6-12 h significantly enhanced UV-induced apoptosis, increased the expression of PARP and p53, and decreased the expression of Mcl-1.Administration of ACBPs did not change the body weight of HCT116 xenograft nude mice, but decreased the tumor growth by approximately 43%, and increased the expression of PARP and p53, and decreased the expression of Mcl-1 in xenograft mouse tumor tissues.

View Article: PubMed Central - PubMed

Affiliation: Clinical Medicine Research Center of the Affiliated Hospital, Inner Mongolia Medical University, Hohhot 010050, China.

ABSTRACT

Aim: We have reported novel anticancer bioactive peptides (ACBPs) that show tumor-suppressive activities in human gastric cancer, leukemia, nasopharyngeal cancer, and gallbladder cancer. In this study, we investigated the effects of ACBPs on human colorectal cancer and the underlying mechanisms.

Methods: Cell growth and apoptosis of human colorectal tumor cell line HCT116 were measured using cell proliferation assay and flow cytometry, respectively. The expression levels of PARP, p53 and Mcl1A were assessed with Western blotting and immunohistochemistry. For evaluation of the in vivo antitumor activity of ACBPs, HCT116 xenograft nude mice were treated with ACBPs (35 μg/mL, ip) for 10 days.

Results: Treatment of HCT116 cells with ACBPs (35 μg/mL) for 4-6 days significantly inhibited the cell growth. Furthermore, treatment of HCT116 cells with ACBPs (35 μg/mL) for 6-12 h significantly enhanced UV-induced apoptosis, increased the expression of PARP and p53, and decreased the expression of Mcl-1. Administration of ACBPs did not change the body weight of HCT116 xenograft nude mice, but decreased the tumor growth by approximately 43%, and increased the expression of PARP and p53, and decreased the expression of Mcl-1 in xenograft mouse tumor tissues.

Conclusion: Administration of ACBPs inhibits human colorectal tumor cell growth and induces apoptosis in vitro and in vivo through modulating the PARP-p53-Mcl-1 signaling pathway.

Show MeSH

Related in: MedlinePlus

ACBPs inhibit the growth of human colorectal tumor HCT116 cells. Cells were seeded at a density of 1000 cells/well in 96-well plates in IMDM medium with 10% FBS. The absorbance at 450 nm was measured for the CCK-8 assay. The results are presented as the mean±SD of three independent experiments. bP<0.05, cP<0.01.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4816232&req=5

fig1: ACBPs inhibit the growth of human colorectal tumor HCT116 cells. Cells were seeded at a density of 1000 cells/well in 96-well plates in IMDM medium with 10% FBS. The absorbance at 450 nm was measured for the CCK-8 assay. The results are presented as the mean±SD of three independent experiments. bP<0.05, cP<0.01.

Mentions: To quantify the inhibitory effect of ACBPs on cell growth, human colorectal tumor HCT116 cells were treated with either ACBPs (35 μg/mL) or vehicle controls. The CCK-8 assay was employed to measure cell growth once daily over a period of 6 d. Our results showed that ACBPs significantly suppressed the growth of HCT116 cells and that their inhibitory effects are time-dependent (Figure 1).


Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway.

Su LY, Shi YX, Yan MR, Xi Y, Su XL - Acta Pharmacol. Sin. (2015)

ACBPs inhibit the growth of human colorectal tumor HCT116 cells. Cells were seeded at a density of 1000 cells/well in 96-well plates in IMDM medium with 10% FBS. The absorbance at 450 nm was measured for the CCK-8 assay. The results are presented as the mean±SD of three independent experiments. bP<0.05, cP<0.01.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4816232&req=5

fig1: ACBPs inhibit the growth of human colorectal tumor HCT116 cells. Cells were seeded at a density of 1000 cells/well in 96-well plates in IMDM medium with 10% FBS. The absorbance at 450 nm was measured for the CCK-8 assay. The results are presented as the mean±SD of three independent experiments. bP<0.05, cP<0.01.
Mentions: To quantify the inhibitory effect of ACBPs on cell growth, human colorectal tumor HCT116 cells were treated with either ACBPs (35 μg/mL) or vehicle controls. The CCK-8 assay was employed to measure cell growth once daily over a period of 6 d. Our results showed that ACBPs significantly suppressed the growth of HCT116 cells and that their inhibitory effects are time-dependent (Figure 1).

Bottom Line: Treatment of HCT116 cells with ACBPs (35 μg/mL) for 4-6 days significantly inhibited the cell growth.Furthermore, treatment of HCT116 cells with ACBPs (35 μg/mL) for 6-12 h significantly enhanced UV-induced apoptosis, increased the expression of PARP and p53, and decreased the expression of Mcl-1.Administration of ACBPs did not change the body weight of HCT116 xenograft nude mice, but decreased the tumor growth by approximately 43%, and increased the expression of PARP and p53, and decreased the expression of Mcl-1 in xenograft mouse tumor tissues.

View Article: PubMed Central - PubMed

Affiliation: Clinical Medicine Research Center of the Affiliated Hospital, Inner Mongolia Medical University, Hohhot 010050, China.

ABSTRACT

Aim: We have reported novel anticancer bioactive peptides (ACBPs) that show tumor-suppressive activities in human gastric cancer, leukemia, nasopharyngeal cancer, and gallbladder cancer. In this study, we investigated the effects of ACBPs on human colorectal cancer and the underlying mechanisms.

Methods: Cell growth and apoptosis of human colorectal tumor cell line HCT116 were measured using cell proliferation assay and flow cytometry, respectively. The expression levels of PARP, p53 and Mcl1A were assessed with Western blotting and immunohistochemistry. For evaluation of the in vivo antitumor activity of ACBPs, HCT116 xenograft nude mice were treated with ACBPs (35 μg/mL, ip) for 10 days.

Results: Treatment of HCT116 cells with ACBPs (35 μg/mL) for 4-6 days significantly inhibited the cell growth. Furthermore, treatment of HCT116 cells with ACBPs (35 μg/mL) for 6-12 h significantly enhanced UV-induced apoptosis, increased the expression of PARP and p53, and decreased the expression of Mcl-1. Administration of ACBPs did not change the body weight of HCT116 xenograft nude mice, but decreased the tumor growth by approximately 43%, and increased the expression of PARP and p53, and decreased the expression of Mcl-1 in xenograft mouse tumor tissues.

Conclusion: Administration of ACBPs inhibits human colorectal tumor cell growth and induces apoptosis in vitro and in vivo through modulating the PARP-p53-Mcl-1 signaling pathway.

Show MeSH
Related in: MedlinePlus